Skip to content
Back to Blog
Bio
2025-11-167 min read58

GLP Test Facility Selection Guide for Bio Companies

How to evaluate and select GLP (Good Laboratory Practice) certified testing facilities for preclinical studies in drug development.

KITIM Consulting Team

GLP Test Facility Selection Guide for Bio Companies

Selecting the right GLP (Good Laboratory Practice) test facility is a critical decision in the drug development process. GLP studies provide the safety data that regulatory authorities rely upon when evaluating new drug applications. A poor facility choice can result in study failures, regulatory delays, and wasted resources. This guide helps bio companies make informed facility selection decisions.

GLP Overview

  • Good Laboratory Practice principles: GLP is a quality system governing the organizational process and conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived, and reported
  • Regulatory significance: GLP compliance is required by MFDS, FDA, EMA, and other regulatory authorities worldwide. Studies conducted at non-GLP facilities are generally not accepted for regulatory submissions
  • Study types covered: GLP applies to single-dose and repeat-dose toxicology, genotoxicity, carcinogenicity, reproductive and developmental toxicology, pharmacokinetics (ADME), and safety pharmacology studies
  • International mutual acceptance: Korea participates in the OECD Mutual Acceptance of Data (MAD) program, meaning GLP studies conducted at Korean-accredited facilities are accepted by regulatory authorities in other OECD member countries
  • Key Evaluation Criteria

    When evaluating potential GLP test facilities, consider these essential criteria:

  • Accreditation status: Verify current GLP accreditation from the relevant national authority (MFDS for Korea) and confirm the scope of accreditation covers your required study types and test species
  • Species capability: Ensure the facility has experience with your required test species (rodent, non-rodent, or non-human primate) and maintains adequate animal housing and husbandry standards
  • Study types: Confirm the facility has demonstrated capability in conducting the specific study types you need, with verifiable track records and relevant experience
  • Staff expertise: Evaluate the qualifications and experience of study directors, principal investigators, and key technical staff, including their familiarity with your product type
  • Capacity and timeline: Assess the facility's current workload and ability to accommodate your study within your required timeline
  • Site Visit Checklist

    A pre-study site visit is strongly recommended before committing to any GLP facility. Key areas to evaluate include:

  • Facility condition: Assess the cleanliness, maintenance, and organization of animal rooms, laboratories, and support areas. Well-maintained facilities reflect overall quality culture
  • QA system: Review the Quality Assurance unit's independence, staffing, inspection schedules, and track record. A robust QA system is the backbone of GLP compliance
  • Study director qualifications: Meet the proposed study director to assess their experience with similar studies, communication style, and availability throughout your study
  • Data management: Evaluate the facility's data capture systems, raw data handling procedures, and archive facilities. Increasingly, electronic data capture systems with audit trails are expected
  • Animal welfare: Observe animal care practices, veterinary oversight, and environmental monitoring. High standards of animal welfare are both ethically important and critical for data quality
  • Regulatory history: Inquire about recent inspection findings from MFDS or other regulatory authorities and how any deficiencies were resolved
  • Cost Considerations

  • Study pricing: GLP study costs vary significantly based on study type, species, group size, and duration. Obtain detailed quotations including all ancillary costs
  • Hidden costs: Be aware of potential additional charges for protocol amendments, unscheduled analyses, extended observation periods, or additional histopathology evaluations
  • Value vs. price: The cheapest facility is rarely the best choice. Consider the total cost of potential study delays, regulatory rejections, or required repeat studies when evaluating pricing
  • Payment terms: Negotiate payment milestones tied to study progress rather than large upfront payments, preserving cash flow flexibility
  • Budget for contingencies: Allocate a contingency budget of 10-15% above the quoted study cost to accommodate unforeseen protocol modifications or additional analyses
  • Common Mistakes in Facility Selection

    Avoid these three critical pitfalls when choosing a GLP test facility:

  • Selecting based on price alone: Choosing the lowest-cost provider without adequate evaluation of quality systems, expertise, and track record often leads to study failures, regulatory queries, and ultimately higher total costs from repeat studies
  • Inadequate due diligence: Skipping the site visit or relying solely on the facility's marketing materials rather than conducting thorough firsthand evaluation of capabilities, systems, and personnel
  • Ignoring communication capabilities: Failing to assess the facility's communication responsiveness and reporting quality. Timely, clear communication throughout the study is essential for identifying and resolving issues before they compromise study integrity
  • How KITIM Can Help

    KITIM assists bio companies with GLP facility evaluation, selection, and study monitoring. Our consultants conduct independent facility assessments, help develop study protocols, and provide oversight throughout the study process. Contact us to ensure your preclinical studies are conducted at facilities that meet the highest standards.

    GLPPreclinical TestingTest Facility

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.